Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 6/20 | 0.65 |
| ▸ | CA1 | P00915 | 6/20 | 0.65 |
| ▸ | CA2 | P00918 | 6/20 | 0.65 |
| ▸ | CA7 | P43166 | 6/20 | 0.65 |
| ▸ | CA9 | Q16790 | 6/20 | 0.65 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.65 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.65 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 4/20 | 0.61 |
| ▸ | XDH | P47989 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | CA4 | P22748 | 2/20 | 0.53 |
| ▸ | CA6 | P23280 | 2/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL162631 | 0.89 | CA12 (0.71) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29501115 | 0.89 | CA12 (0.71) | CA12CA1CA2CA7CA9 | |
| SCHEMBL10564137 | 0.87 | CA12 (0.69) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1647438 | 0.85 | CA12 (0.65) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9122345 | 0.85 | CA12 (0.67) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5082071 | 0.85 | SMN1; SMN2 (0.65) | CA12CA1CA2CA7CA9 | |
| SCHEMBL820141 | 0.85 | KDM4E (0.55) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29699657 | 0.85 | KDM4E (0.55) | CA12CA1CA2CA7CA9 | |
| SCHEMBL20414588 | 0.84 | CA12 (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1018113 | 0.83 | KDM4E (0.53) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112980041-A | Preparation method of anti-yellowing high-strength expanded polystyrene heat-insulating material | 长沙三思新材料科技有限公司 | 2021-06-18 | — | — | CN | claimed |
| CN-118079661-A | Two-dimensional porous frame-based mixed matrix membrane, and preparation method and separation application thereof | 中国科学院大连化学物理研究所 | 2024-05-28 | — | — | CN | disclosed |
| US-20230160000-A1 | SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230160000-A1 | SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230028321-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230028388-A1 | DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-01-26 | — | — | US | disclosed |
| US-20220411860-A1 | DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-12-29 | — | — | US | disclosed |
| CN-114728064-A | Antibody-containing preparation | 中外制药株式会社 | 2022-07-08 | — | — | CN | disclosed |
| WO-2021252723-A1 | LINKER-FUNCTIONALIZED METAL-ORGANIC FRAMEWORK FOR POLYSULFIDE TETHERING IN LITHIUM-SULFUR BATTERIES | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-12-16 | — | — | WO | disclosed |
| US-11085076-B2 | Synthesis of novel disulfide linker based nucleotides as reversible terminators for DNA sequencing by synthesis | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-08-10 | — | — | US | disclosed |
| US-20080027068-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2008-01-31 | — | — | US | disclosed |
| EP-1879940-A1 | PREPARATION OF LOW-ACID POLYALKYLENE TEREPHTHALATE AND PREPARATION OF MACROCYCLIC POLYESTER OLIGOMER THEREFROM | Cyclics Corporation (US) | 2008-01-23 | — | — | EP | disclosed |
| US-20060235233-A1 | Methods for removing catalyst residue from a depolymerization process stream | CYCLICS CORPORATION (US) | 2006-10-19 | — | — | US | disclosed |
| US-20060235186-A1 | Use of a residual oligomer recyclate in the production of macrocyclic polyester oligomer | CYCLICS CORPORATION (US) | 2006-10-19 | — | — | US | disclosed |
| US-20060235185-A1 | Preparation of low-acid polyalkylene terephthalate and preparation of macrocyclic polyester oligomer therefrom | CYCLICS CORPORATION (US) | 2006-10-19 | — | — | US | disclosed |
| WO-2006104821-A1 | PREPARATION OF LOW-ACID POLYALKYLENE TEREPHTHALATE AND PREPARATION OF MACROCYCLIC POLYESTER OLIGOMER THEREFROM | CYCLICS CORPORAITON (US) | 2006-10-05 | — | — | WO | disclosed |
| CN-1798739-A | 3-alkylidenehydrazino substituted heteroaryl compounds as thrombopoietin receptor activators | NISSAN CHEMICAL IND LTD (JP) | 2006-07-05 | — | — | CN | disclosed |
| US-20060094694-A1 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1636192-A1 | 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | Nissan Chemical Industries, Ltd. (JP) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004108683-A1 | 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411860-A1 | DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | POLL, POLQ, POLB | CA12 4147/4885CA1 3823/4885CA2 4528/4885 |
| US-20060094694-A1 | Heterocyclic compounds and thrombopoietin receptor activators | NR2C2, ROR1, NR0B2 | CA12 1026/4885CA1 2516/4885CA2 2631/4885 |
| US-20230028388-A1 | DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | RNGTT, POLRMT, MTR | CA12 4243/4885CA1 3884/4885CA2 4348/4885 |
| US-20060235233-A1 | Methods for removing catalyst residue from a depolymerization process stream | MPO, CAT, LPO | CA12 526/4885CA1 386/4885CA2 1245/4885 |
| US-20080027068-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NR2C2, ROR1, NR0B2 | CA12 1203/4885CA1 2676/4885CA2 2832/4885 |
| US-11085076-B2 | Synthesis of novel disulfide linker based nucleotides as reversible terminators for DNA sequencing by synthesis | POLRMT, RNGTT, MTR | CA12 4130/4885CA1 3850/4885CA2 4253/4885 |
| US-20230028321-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | POLRMT, NSUN2, NUDT1 | CA12 3711/4885CA1 4662/4885CA2 4663/4885 |
| US-20230160000-A1 | SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | POLRMT, RNGTT, MTR | CA12 4130/4885CA1 3850/4885CA2 4253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.